

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

ZIMMERMANN ET AL.

Examiner: Emily Bernhardt

APPLICATION NO: 09/463,097

FILED: JANUARY 18, 2000

FOR: CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINEAMINE
DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS
USE

RECEIVED
OCT 22 2004
OFFICE OF PETITIONS

MS: 313©

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

PETITION UNDER 37 CFR §1.313(c)(2) TO WITHDRAW APPLICATION FROM ISSUE

Sir:

Applicant respectfully petitions for the withdrawal from issuance of the above-identified patent application. Submitted herewith is a Request for Continued Examination of the above-identified application. Applicant is petitioning for the withdrawal from issue of the present application, and is filing a Continued Prosecution Application Request, in order that an Information Disclosure Statement be considered by the U.S. Patent and Trademark Office. Applicants request consideration by the Examiner of additional references which have recently come to the attention of the undersigned attorney. Please charge the petition fee of \$130 pursuant to 37 CFR §1.17(h) to Deposit Account Number 19-0134 in the name of Novartis.

Respectfully submitted,



George F. Dohmann
Attorney for Applicants
Reg. No. 33,593

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7824

Date: October 21, 2004

10/25/2004 AKELLEY 00000003 190134 09463097

01 FC:1460 130.00 DA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

ZIMMERMANN ET AL.

Examiner: Emily Bernhardt

APPLICATION NO: 09/463,097

FILED: JANUARY 18, 2000

FOR: CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINEAMINE
DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS
USE

RECEIVED
OCT 22 2004
OFFICE OF PETITIONS

MS: 313©

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

PETITION UNDER 37 CFR §1.313(c)(2) TO WITHDRAW APPLICATION FROM ISSUE

Sir:

Applicant respectfully petitions for the withdrawal from issuance of the above-identified patent application. Submitted herewith is a Request for Continued Examination of the above-identified application. Applicant is petitioning for the withdrawal from issue of the present application, and is filing a Continued Prosecution Application Request, in order that an Information Disclosure Statement be considered by the U.S. Patent and Trademark Office. Applicants request consideration by the Examiner of additional references which have recently come to the attention of the undersigned attorney. Please charge the petition fee of \$130 pursuant to 37 CFR §1.17(h) to Deposit Account Number 19-0134 in the name of Novartis.

Respectfully submitted,



George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7824

Date: October 21, 2004